Jacobson Pharma Corporation Ltd. and JBM (Healthcare) Limited have jointly announced the signing of the 2025 Europharm License Agreement. The agreement follows the expiration of the previous 2020 License Agreement on 30 November 2025. The new license arrangement is considered by the boards of both companies to be in the ordinary and usual course of business, with terms deemed fair, reasonable, and in the best interests of shareholders. The agreement constitutes a continuing connected transaction under Chapter 14A of the Hong Kong Listing Rules. As the applicable percentage ratios are below 5% but the total considerations exceed HK$3,000,000, the agreements are subject to reporting and announcement requirements but are exempt from circular and independent shareholders' approval requirements. Directors with potential conflicts of interest abstained from voting on the relevant resolutions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobson Pharma Corporation Ltd. published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.